Asset Details
Do you wish to reserve the book?
Infliximab (Remicade®)
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Infliximab (Remicade®)
Do you wish to request the book?
Infliximab (Remicade®)
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Book Chapter
Infliximab (Remicade®)
2014
Overview
Infliximab was not only one of the first antibodies developed as a therapeutic, but also one of the first drugs targeting a cytokine. The inhibition of the cytokine TNFα has proven effective in a wide variety of chronic inflammatory diseases pointing to the central role of TNFα in the inflammatory process. While immunosuppression through TNFα inhibition results in benefits to patients ranging from amelioration of symptoms, inhibition of structural damage, and improvement of quality of life, it also carries risks in higher susceptibility to infection and malignancies. Recent advancements in therapies targeting other members of the cytokine family are also demonstrating benefits in efficacy and safety in many diseases, but do not appear to be as universally applicable to a variety of indications as anti‐TNF treatment.
Publisher
Wiley‐VCH Verlag GmbH & Co. KGaA
Subject
ISBN
9783527329373, 3527329374
